<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347477">
  <stage>Registered</stage>
  <submitdate>14/09/2011</submitdate>
  <approvaldate>16/09/2011</approvaldate>
  <actrnumber>ACTRN12611000987965</actrnumber>
  <trial_identification>
    <studytitle>Maya Renal Hypertension Ablation System Study</studytitle>
    <scientifictitle>Low Level RF Renal Ablation in Chronic Hypertensive Patients to Treat Resistancy to Anti Hypertensive Medication By Lowering Systolic Blood Pressure</scientifictitle>
    <utrn>NIL</utrn>
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Balloon Catheter delivers low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney. The treatment time is approximately 2 minutes. Catheter is removed from the body at the end of procedure.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ability to insert the balloon catheter and place it within the renal artery and safely remove it from the body.</outcome>
      <timepoint>Procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ability to deliver low level RF energy to the renal artery.</outcome>
      <timepoint>Procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Measuring the RF energy delivered and the duration of energy delivered.</outcome>
      <timepoint>Procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood Pressure Reduction will be assessed by measuring blood pressure with a standard sphygmomanometer or manual measurement system. Three separate measurements will be averaged to yield the clinical assessment.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subject has a systolic blood pressure greater than or equal to 160 mmHg 
Subject is on 2 or more anti hypertensive medications
Bilateral Renal Arteries must be between 4-7mm diameter and greater than 20mm in length
Subject signs informed consent and agrees to follow up visits</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subject has a glomerular filtration rate (eGFR) of &lt; 45mL/min/1.73m2, using the MDRD calculation.
Subject has had a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit.
Subject has history of bleeding diathesis or coagulopathy, Type 1 diabetes, renal artery stenosis, valve disease, planned surgery or intervention in coming 6 months, allergy to listed drugs in protocol, is pregnant, or has peripheral disease precluding a 9F sheath introducer.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/11/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Maya Medical</primarysponsorname>
    <primarysponsoraddress>18729 Metler Court
Saratoga, California 95070</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Maya Medical</fundingname>
      <fundingaddress>18729 Metler Court
Saratoga, California 95070</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Mike Kolber Regulatory Affairs Maya Medical</sponsorname>
      <sponsoraddress>18729 Metler Court
Saratoga, California 95070</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>PCRG</othercollaboratorname>
      <othercollaboratoraddress>Pacific Clinical Research Group Pty Limited
Suite G03,1 Cassins Avenue
North Sydney  Sydney NSW 2060
Australia</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>An initial evaluation of the Maya Renal Hypertension Ablation System for the treatment of subjects with chronic resistant hypertension</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mercy Angiography Mercy Hospital Ethics Committee</ethicname>
      <ethicaddress>Mercy Hospital 
98 Mountain Rd, 
Auckland, NZ, 1003</ethicaddress>
      <ethicapprovaldate />
      <hrec>NTX/11/09/091</hrec>
      <ethicsubmitdate>3/09/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Michel Accad</name>
      <address>2000 Van Ness Ave
Suite 208
San Francisco, CA 94109</address>
      <phone>+0014153772868</phone>
      <fax>+0019494940557</fax>
      <email>draccad@draccad.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Whit Rice</name>
      <address>18729 Metler Court
Saratoga California 95070</address>
      <phone>+0014089034092</phone>
      <fax>+0019494940557</fax>
      <email>whit@shifamed.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Laura Minarsch</name>
      <address>430 Forest Ave
Laguna Beach, California 92651</address>
      <phone>+0019492805700</phone>
      <fax>+0019494940557</fax>
      <email>laura22@mmc-medical.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>